Omisirge market seen growing as personalized cell therapy demand rises
The Business Research Company says the Omisirge market is set for continued growth through 2026 to 2035, driven by rising blood cancer cases, broader use of allogeneic stem cell transplants and demand for personalized therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.
Why it matters: - Omisirge targets a high-need area of care: patients undergoing allogeneic hematopoietic stem cell transplantation for blood cancers and related disorders. - Faster neutrophil recovery can lower infection risk and other post-transplant complications, making treatment outcomes and recovery times more important commercially and clinically. - The market outlook points to broader demand for advanced cell therapies as healthcare systems shift toward more personalized treatment options.
What happened: - The Business Research Company published its Omisirge Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on November 9, 2026. - The report says the Omisirge market is gaining attention because of its role in improving outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation. - The report also says market growth has been supported by rising blood cancer incidence, challenges with traditional cord blood transplants and early clinical success for cell expansion technologies. - A free sample of the report is available here. - The full report is available here.
The details: - Omisirge is a cell therapy used in allogeneic HSCT for patients with blood cancers or disorders. - The therapy is derived from umbilical cord blood. - Omisirge is engineered to speed neutrophil recovery after transplantation. - The product consists of expanded hematopoietic progenitor cells (CD34+) that are cultured to increase quantity and functional capacity. - The report says this approach enables faster engraftment than standard cord blood transplantation. - The report says growth is also being fueled by increasing use of allogeneic stem cell transplants and regulatory approvals for advanced cell therapies. - Additional growth drivers include broader personalized cell therapy pipelines, higher investment in regenerative medicine, wider use of advanced transplantation protocols and a focus on reducing post-transplant complications. - Emerging trends include expanded cord blood therapies, ex vivo cell expansion techniques, faster neutrophil engraftment, broader HSCT applications and more scalable manufacturing for cell-based treatments. - The report says demand for personalized treatments is helping the market because these therapies are designed around individual genetic, environmental and lifestyle factors. - In February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.
Between the lines: - The report frames Omisirge as part of a broader shift toward therapies that improve transplant performance rather than simply replace older methods. - Faster engraftment and fewer complications are the commercial hooks, but manufacturing scalability will likely determine how widely cell therapies can expand. - The personalized medicine backdrop suggests Omisirge is riding a larger regulatory and clinical trend, not just a single-product story.
What's next: - The report expects the Omisirge market to keep expanding through 2035 as personalized cell therapy pipelines deepen and regenerative medicine investment grows. - North America held the largest market share in 2025. - Asia-Pacific is projected to grow fastest over the forecast period because of improving healthcare access, rising cell therapy investment and higher patient demand. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspot infographics, and updated technology and trend analysis. - More information is available through the company’s LinkedIn page, Facebook page and X account.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Africa News Guide
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.